Navigation Links
Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4,Inhibitor, ARI-2243, at the ADA

- ARI-2243 is an highly potent DPP-4 inhibitor, possessing Ki of 27 pM

BOSTON, June 25, 2007 /PRNewswire/ -- Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, announced today the results of its potent, smart DPP-4 inhibitor, ARI-2243, presented at the 67th session of the American Diabetes Association meeting in Chicago, Illinois. The results showed that ARI-2243 is an extremely long acting, potent inhibitor of DPP-4 and produced superior reductions in plasma glucose compared with sitagliptin in oral glucose tolerance test (OGTT) in mice. Additionally, ARI-2243 produced significant reduction in hemoglobin A1c levels (HbA1c) following 9 weeks of daily oral dosing in an highly refractory diabetic animal model compared with no significant change with vildagliptin. The long-acting and potent attributes of ARI-2243 are expected to confer a differentiated efficacy profile in diabetic patients. Arisaph is currently completing IND enabling studies and expects to initiate first-in-man testing in 2008.

Arisaph designed ARI-2243 as a once a day, orally active, smart DPP-4 inhibitor that is highly potent and functionally selective. In vitro kinetic studies show that ARI-2243 has an affinity (Ki) of 27 picomolar, binding tightly to DPP-4 and dissociating very slowly from the enzyme. Such binding kinetics confer potency and long activity. Specifically, during OGTT in normal mice, ARI-2243 produced far greater lowering of plasma glucose compared with sitagliptin. Specifically, the ED50 with ARI-2243 was 0.006 mg/kg compared with sitagliptin, which had an ED50 of 1.5 mg/kg. Moreover, at 18 hours post dose, ARI-2243 lowered plasma AUC 25%, demonstrating long duration of action of the smart inhibitor.

In ZDF rats, an animal model that develops overt diabetes, ARI-2243 produced a significant reduction in HbA1c of 2.5% and 2.2% versus placebo and vildagliptin, respectively follo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:8/29/2014)... Aug. 29, 2014 The Competitive Intelligence (CI) ... marketplace changes. CI leaders who adjust will succeed, and ... a new Best Practices, LLC study CI leaders from ... including: - Use secondary research whenever possible ... - Internal staff who are creative thinkers ...
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP has ... or the "Company") (NASDAQ: EDAP ) and ... United States District Court, Southern District of ... on behalf of a class consisting of all persons ... 2013 and July 30, 2014, inclusive (the "Class Period"). This ...
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Calif., March 1, 2012  Bionovo, Inc. (OTC Link Platform: BNVI.PK), ... safe and effective treatments for women,s health and cancer, today ... President, will be presenting at the Cowen and Company 32nd ... 5, 2012.  The event will be held at the Boston ...
... England, March 1, 2012 Some of the ... cutting thousands of medical sales jobs in order to slash ... the industry. Biopharmaceutical giants AstraZeneca were the first ... be axed in 2012. The company has already seen an ...
Cached Medicine Technology:Job Cuts from Major Pharmaceutical Firms Results in Tougher Competition, Says Advance Recruitment 2
(Date:9/1/2014)... "Women struggle with weight gain typically associated ... as early as 15, if not earlier. Women ... and downs of hormone related weight gain. The ... seems to rage against the hidden and ever-present hormones ... 40's begin to face menopause and related changes, these ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 As well ... training, Derek is currently pursuing counselor certification in Louisiana. ... advance through the CPI training program as well as ... I have grown both personally and professionally. I ... I am competently able to do so. As ...
(Date:9/1/2014)... 01, 2014 Parties involved in federally-filed ... the litigation’s status conference in September, where issues related ... in the Eastern District of Pennsylvania, Bernstein Liebhard LLP ... conferences posted on the Court’s website, the meeting is ... 10:00 a.m. This is the latest of several Tylenol ...
(Date:9/1/2014)... The Outlier Series announced the next ... content from one of the exceptional women featured in ... Game Changers . The title of the upcoming mini ... Jenny McClendon . McClendon is currently a full-time physician’s ... star of WeTV show, Raising Sextuplets. , Jenny was ...
(Date:9/1/2014)... 01, 2014 Psychogenic Non-epileptic Seizures (PNES), ... psychological disorder that can have devastating effects on those ... epileptic seizures however, they are not produced by electrical ... It is estimated that the numbers of persons ... multiple sclerosis. , Dr. Lorna Myers, Director ...
Breaking Medicine News(10 mins):Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... adolescent lacrosse and hockey players have been found to ... them at increased risk of serious injuries// such as ... been published in the Journal of Sport Medicine. ... ‘helmet boxing’—is an underrecognized activity that needs to be ...
... the Douglas Hospital Research Centre (DHRC) in Montreal, Canada, has ... and consequently that their daughters make more attentive mothers. // ... studies, highlight the importance of a positive environment not only ... ,“There is an old adage that applies to our ...
... new generation drug that can treat breast cancer. But NHS said ... stages of breast cancer. // Due to this there are lots ... care providers to pay for the drug. The latest being a ... He was told that his local NHS trust would fund for ...
... could be allowed to use IVF to have children free ... be discussed by the government's fertility watchdog tomorrow for approval. ... allowed to select embryos free from genes that can cause ... Fertilisation and Embryology Authority (HFEA) would permit thousands of women ...
... from immune mice, have an innate immunity ,against cancer, ... forms of cancer treatment. When such ,cells were introduced ... confer a lifelong immunity against the ,much-dreaded disease. ... presence of a biological pathway in a specific species. ...
... news study appearing in the June 15, 2006 issue ... Society, says that external beam radiation// could be a ... diagnosed with prostate cancer. ,Age has remained ... cancer. In younger individuals, doctors recommend more aggressive therapy ...
Cached Medicine News:Health News:Teen Players Urged To Wear Helmets and Gloves to Avoid Sports Injuries 2Health News:Love Mom More 2Health News:Women With Breast Cancer Can Now USE IVF To Spare Their Daughters 2Health News:Women With Breast Cancer Can Now USE IVF To Spare Their Daughters 3Health News:Tumor Resistant Mice Point To Novel Cancer Treatments 2
The humidity chamber maintains a moist environment during immunostaining procedures as well as other laboratory procedures requiring controlled incubation steps....
Used to remove wrinkles from sections and for reorientating embedded tissue....
Prevents formation of microscopic ice crystals and sample distortion caused by slow freezing of hyperosmolar tissue samples in conventional cyrostats....
Liquichek Blood Gas Plus EGL Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2, electrolytes, glucose and lactate (lactic acid)....
Medicine Products: